Abiopharma

Johnson & Johnson - New TECVAYLI®(teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

PPG destaca avanço rumo às metas de 2030 no Relatório de Sustentabilidade 2025

PPG destaca los avances en el cumplimiento de sus objetivos para 2030 en su Informe de Sustentabilidad 2025

MidOcean Partners Signs Definitive Agreement to Sell Zonda to CoStar Group

Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio

Purchase plan approval

Why Single-Chain Troponin I–C Fusion Proteins Are Transforming Cardiac Immunoassay Calibration

SAIC Board of Directors Declares Cash Dividend